Strand Therapeutics
13 articles about Strand Therapeutics
-
Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors
1/22/2024
Strand Therapeutics today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of STX-001, a multi-mechanistic synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly into the tumor microenvironment.
-
Strand Therapeutics Appoints Colleen Wilson as Chief People Officer
4/24/2023
Strand Therapeutics today announced the appointment of Colleen Wilson as Chief People Officer.
-
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
4/17/2023
Strand Therapeutics announced today preclinical data from its programmable mRNA therapy STX-001, a multi-modal synthetic self-replicating mRNA technology that delivers a prolonged and locally-acting IL-12 cytokine to the tumor microenvironment.
-
Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting
3/14/2023
Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14 - 19, 2023 in Orlando, Florida.
-
Strand Therapeutics Appoints Jay Stella as Chief Business Officer
3/1/2023
Strand Therapeutics today announced the appointment of Jay Stella, MBA as Chief Business Officer.
-
Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million
11/28/2022
Strand Therapeutics , the programmable mRNA company developing curative therapies for cancer and other diseases, today announced it has added an additional $45M to its Series A financing round, bringing the total amount raised in the Series A to $97 million.
-
Fierce Biotech names Strand Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
9/12/2022
Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development
2/8/2022
Strand Therapeutics today announced that Prashant Nambiar, DVM, PhD, MBA has been appointed Senior Vice President, Research and Translational Development.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma
11/9/2021
Strand Therapeutics today announced that the company was awarded a Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI)
-
Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35
6/30/2021
Today, Strand Therapeutics, announced Jake Becraft, PhD, co-founder and CEO of Strand, has been named to MIT Technology Review’s prestigious annual list of Innovators Under 35.
-
Strand Therapeutics Raises $52M in Oversubscribed Series A Round
6/23/2021
Strand Therapeutics today announced that the company raised $52 million in an oversubscribed Series A financing round.